PER 0.00% 10.5¢ percheron therapeutics limited

Ann: Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy, page-49

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 35,751 Posts.
    lightbulb Created with Sketch. 554
    lol i'm just impressed Imperatore gave me such a long love/hate post.

    I didn't even start referring to other companies it was Booomy & Itsgas - i just cleared it up.

    Surprised i have to do it though with ItsGas and all his self-praise as master of DD slipping?

    I previously stated with the pre-clinical limb-girdle study i didn't have much expectation (despite pumps here as always lol), interesting of course but i don't see anything much happening with it outside of further studies in the near term. These things take time and resources - don't forget from completion of the IIa study it has taken 3 years to get to now having the first patient dosed in the IIb.

    All focus on recruitment rates and last pt dosed in IIb to paint a timeline into the future.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.